Company Collaboration and Strategy - DarioHealth Corp announced a collaboration with MediOrbis to enhance its GLP-1 behavior change solution by adding prescribing capabilities, creating a fully integrated medical weight loss program [1] - The collaboration aims to meet growing employer demand for weight-loss medication coverage and expand Dario's addressable market in the digital health sector [1] - The partnership positions Dario to drive recurring revenue and expand its market presence in both employer and direct-to-consumer channels [1][4] Market Trends and Employer Demand - 44% of large employers now cover obesity drugs, reflecting a growing trend in employer-sponsored health benefits [2] - The rising costs of GLP-1 medications highlight the need for strategic plan designs that combine medication use with behavior change programs to ensure sustainable clinical outcomes and maximize ROI [2] - Employers are increasingly seeking holistic, cost-effective weight management solutions, creating opportunities for Dario to optimize outcomes and ROI through its integrated offerings [2][3] Product and Service Enhancements - Dario's GLP-1 behavior change solution now includes virtual physician oversight and prescribing capabilities, enabling seamless access to care throughout the weight loss journey [1][3] - The enhanced solution supports employees before, during, and after GLP-1 medication use, ensuring sustainable weight loss through lifelong healthy lifestyle modifications [2][3] - The collaboration strengthens Dario's ability to provide personalized, high-quality virtual care that complements its behavior change programs, delivering meaningful health outcomes [4] Industry and Market Positioning - The GLP-1 market is rapidly expanding, with employers demanding solutions that drive long-term health improvements and cost savings [4] - Dario's end-to-end GLP-1 solution, combining virtual prescribing with behavior change programs, positions the company to capture opportunities in both employer and direct-to-consumer markets [4] - The collaboration with MediOrbis allows Dario to innovate and develop clinical programs that address obesity and other chronic conditions, impacting employee health and productivity globally [4] Company Overview - DarioHealth Corp is a leading digital health company offering a user-centric, multi-chronic condition digital therapeutics platform [5] - The platform delivers personalized interventions for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health, driven by data analytics and one-on-one coaching [5] - Dario's solutions are highly rated and provided globally to health plans, self-insured employers, care providers, and consumers [7]

Company expects to reach an estimated total of 25 new client signings in 2024, representing an approximate 35% growth in client base compared to 2023NEW YORK, Nov. 21, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today the signing of four contracts with self-insured employers that are expected to go live in the first quarter of 2025.Dario has added four new employer contracts to the 2025 book of business, continuing ...

DarioHealth Corp. (NASDAQ:DRIO) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Kat Parrella - Investor Relations Manager Erez Raphael - Chief Executive Officer Steven Nelson - Chief Commercial Officer Operator Good morning, ladies and gentlemen, and welcome to the DarioHealth Third Quarter 2024 Results Call. [Operator Instructions] This call is being recorded on November 7, 2024. I would now like to turn the conference over to Kat Parrella, Investor Relations Manager at Dar ...

DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.49 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 27.78%. A quarter ago, it was expected that this company would post a loss of $0.29 per share when it actually produced earnings of $0.06, delivering a surprise of 120.69%.Over the last four quarters, the company has sur ...

Financial Performance - Q3 2024 revenue reached $7.42 million, an 18.7% increase from Q2 2024 and a 111% increase compared to Q3 2023, driven by growth in the B2B2C business [4][13] - Q3 operating loss decreased by 25.7% sequentially to $12 million on a GAAP basis and by 33.3% to $7.1 million on a non-GAAP basis [1][7] - Gross profit for Q3 2024 was $3.9 million, a 534% increase compared to Q3 2023, with gross margins reaching 52.2% [15] - Pro-forma gross profit for Q3 2024 was $5.2 million, or 70.3% of revenues, excluding $1.34 million of amortization expenses [16] Business Momentum and Strategic Wins - Secured 10 new B2B2C clients, including a national Medicare advantage health plan, a regional Medicaid health plan, and a global leading pharma company [1][9] - Transformed the pharma/medical device channel into a recurring revenue model, securing two new deals, including one with a top six global pharma company [1][10] - Completed the integration of Twill's capabilities, creating a comprehensive digital health solution under the Dario brand [11] Cost Management and Synergies - Implemented cost-management strategies post-Twill acquisition, reducing GAAP operating expenses by 16% sequentially to $15.9 million and non-GAAP operating expenses by 15.9% to $12.3 million [6] - Expected to reduce operating expenses by 38% by Q1 2025 compared to Q1 2024, contributing to a 49% reduction in operating losses and a 59% reduction in non-GAAP operating losses [1][8] Future Outlook - On track to achieve operational cash flow breakeven run rate by the end of 2025 [1][8] - Anticipates continued revenue growth and increasing gross margins due to positive mix shift and reduced fixed expenses [8] Industry and Market Position - DarioHealth is a leader in the global digital health market, offering a multi-chronic condition digital therapeutics platform [2][29] - The company's AI capabilities, including generative AI and microservices, are expected to revolutionize areas like drug discovery and consumer engagement [12]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37704 | --- | --- | |------------------------------------------------------------------------------------------- ...

The new contract marks the eighth health plan for Dario and will contribute to revenues starting immediately. NEW YORK, Oct. 30, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract with a regional health plan in the Medicaid space, which has launched with the full suite of cardiometabolic solutions. The launch with this new health plan marks the third Medicaid client for Dario, continuing a solid momen ...

Company to host conference call and webcast at 8:30am ETNEW YORK, Oct. 23, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a global leader in digital health, announced today that it will release its financial results for the 3rd quarter ended September 30th, 2024 and will host a conference call and webcast at 8:30 am Eastern Time, on Thursday, November 7th, 2024, before the market opens.Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will ...

Integration of behavioral health and wellbeing solutions with navigation and engagement technology creates the most comprehensive solution in the market under the Dario brand NEW YORK, Oct. 17, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a global leader in digital health, today announces the full integration of Twill's advanced behavioral health and navigation capabilities into the Dario platform. The integration completes Dario's effort to create one of the most compre ...

New offer gives Dario access to millions of AARP members, enabling engagement with people over 50 in health and well-being beginning in January 2025 NEW YORK, Oct. 15, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new AARP member benefit that provides members with proven digital behavioral health and well-being solutions from Twill by Dario. The new benefit is expected to launch in January of 2025 for AARP me ...